Neuraxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuraxis, Inc. (NRXS) on November 15, 2024, covering events occurring on November 9, 2024. The Company, incorporated in Delaware and listed on NYSE American, is an emerging growth company. The report details a material definitive agreement and unregistered sales of equity securities.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. The primary financial event reported is a capital raise transaction:
- Transaction Amount: Approximately $5 million aggregate purchase price.
- Securities Issued: 2,100,840 shares of Series B Convertible Preferred Stock.
- Stated Value: $2.38 per share.
- Investors: Three related investors.
- Closing Date: November 13, 2024.
Material Changes and Agreements
The Company entered into Securities Purchase Agreements (SPAs) and amended its Certificate of Designation for Series B Preferred Stock. Key changes include:
- Authorized Shares: Increased from 4,000,000 to 5,000,000 shares.
- Dividend Rights: Extended from June 30, 2025, to December 31, 2026.
- Registration Rights: The Company must file a resale registration statement within 30 days of execution and have it declared effective within 60 days (or 90 days if fully reviewed).
- Liquidated Damages: Failure to meet registration deadlines triggers cash penalties of 1% of the subscription amount per month, capped at 6%. Unpaid penalties incur 18% annual interest.
Outlook, Risks, and Contingencies
The filing highlights specific contractual risks associated with the registration rights obligations. If the Company fails to file or declare the registration statement effective within the stipulated timelines, it faces mandatory cash payments to investors. The issuance was exempt from registration under Section 4(a)(2) of the Securities Act as a private placement to accredited investors.
Investor Verification Checklist
- Verify the execution of the Registration Rights Agreements and the timeline for the resale registration statement filing.
- Confirm the impact of the 1% monthly liquidated damages clause on future cash flow if registration deadlines are missed.
- Review the full text of the Fourth Amendment to the Certificate of Designation (Exhibit 10.1) for additional terms regarding the Series B Preferred Stock.
- Assess the dilution impact of the 2,100,840 convertible shares on existing common stockholders.